News

Catalyst Series – Lineage Cell Therapeutics (LCTX)

Health
0 min read

This is Catalyst – a new short-form video series that asks senior executives the questions investors want answered. Exclusively on Channelchek. Brian Culley, CEO of Lineage Cell Therapeutics provides an update on the company’s OpRegen program for the treatment of dry age-related macular degeneration and answers questions regarding the latest developments with Lineage’s OPC1 program for spinal cord injury, and how they are managing in the current challenging biotech environment. All in less than three minutes.

Research, News, and Advanced Market Data on LCTX

Comments

0
No comments yet...
Share

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2022 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.